Abstract
43 patients with advanced breast cancer, resistant to conventional therapies, were treated with mitomycin C at a dose of 20 mg/m2 i.v. every 6 weeks. No response was observed. The most common side effect was myelotoxicity. Leukopenia occurred in 63% of the patients, thrombocytopenia in 67%, and anemia in 14%. Two episodes of acute dyspnea were observed which were thought to be pulmonary hypersensitivity reactions. This study does not suggest that mitomycin C is of value as second- or third-line treatment in metastatic breast cancer. It is likely that the drug could play a more important role in combination with other chemotherapeutic agents.
| Original language | English |
|---|---|
| Pages (from-to) | 244-247 |
| Number of pages | 4 |
| Journal | Oncology |
| Volume | 40 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1983 |
Fingerprint
Keywords
- Breast cancer
- Chemotherapy
- Mitomycin C
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy. / Lopez, Massimo; Papaldo, Paola; Di Lauro, Luigi; Barduagni, Mario; Perno, Carlo Federico; Barduagni, Aldo.
In: Oncology, Vol. 40, No. 4, 1983, p. 244-247.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy
AU - Lopez, Massimo
AU - Papaldo, Paola
AU - Di Lauro, Luigi
AU - Barduagni, Mario
AU - Perno, Carlo Federico
AU - Barduagni, Aldo
PY - 1983
Y1 - 1983
N2 - 43 patients with advanced breast cancer, resistant to conventional therapies, were treated with mitomycin C at a dose of 20 mg/m2 i.v. every 6 weeks. No response was observed. The most common side effect was myelotoxicity. Leukopenia occurred in 63% of the patients, thrombocytopenia in 67%, and anemia in 14%. Two episodes of acute dyspnea were observed which were thought to be pulmonary hypersensitivity reactions. This study does not suggest that mitomycin C is of value as second- or third-line treatment in metastatic breast cancer. It is likely that the drug could play a more important role in combination with other chemotherapeutic agents.
AB - 43 patients with advanced breast cancer, resistant to conventional therapies, were treated with mitomycin C at a dose of 20 mg/m2 i.v. every 6 weeks. No response was observed. The most common side effect was myelotoxicity. Leukopenia occurred in 63% of the patients, thrombocytopenia in 67%, and anemia in 14%. Two episodes of acute dyspnea were observed which were thought to be pulmonary hypersensitivity reactions. This study does not suggest that mitomycin C is of value as second- or third-line treatment in metastatic breast cancer. It is likely that the drug could play a more important role in combination with other chemotherapeutic agents.
KW - Breast cancer
KW - Chemotherapy
KW - Mitomycin C
UR - http://www.scopus.com/inward/record.url?scp=0020523976&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020523976&partnerID=8YFLogxK
U2 - 10.1159/000225736
DO - 10.1159/000225736
M3 - Article
C2 - 6408547
AN - SCOPUS:0020523976
VL - 40
SP - 244
EP - 247
JO - Oncology
JF - Oncology
SN - 0030-2414
IS - 4
ER -